Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2018
At a glance
- Drugs BAY 1161116 (Primary) ; Itraconazole
- Indications Polycystic ovary syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 16 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2018 Planned End Date changed from 18 Dec 2017 to 23 Jan 2018.
- 21 Nov 2017 Planned End Date changed from 29 Nov 2017 to 18 Dec 2017.